FR2866567A1 - Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee - Google Patents

Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee

Info

Publication number
FR2866567A1
FR2866567A1 FR0401715A FR0401715A FR2866567A1 FR 2866567 A1 FR2866567 A1 FR 2866567A1 FR 0401715 A FR0401715 A FR 0401715A FR 0401715 A FR0401715 A FR 0401715A FR 2866567 A1 FR2866567 A1 FR 2866567A1
Authority
FR
France
Prior art keywords
beta
adrenergic
compounds
metronidazole
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR0401715A
Other languages
English (en)
Inventor
Fabrizio Folfi
Irina Safonova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0401715A priority Critical patent/FR2866567A1/fr
Priority to CA002553208A priority patent/CA2553208A1/fr
Priority to PCT/FR2005/000367 priority patent/WO2005089871A1/fr
Priority to US10/590,077 priority patent/US20070275978A1/en
Priority to EP05729329A priority patent/EP1722855A1/fr
Publication of FR2866567A1 publication Critical patent/FR2866567A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Abstract

L'invention se rapporte à l'utilisation d'un composé antagoniste d'au moins un récepteur choisi dans le groupe comprenant les récepteurs bêta-adrénergiques, le récepteur AT1, le récepteur 5-HT2, le récepteur 5-HT5, et le récepteur de la galanine, pour la préparation d'une composition pharmaceutique destinée au traitement de la rosacée.
FR0401715A 2004-02-20 2004-02-20 Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee Pending FR2866567A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0401715A FR2866567A1 (fr) 2004-02-20 2004-02-20 Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee
CA002553208A CA2553208A1 (fr) 2004-02-20 2005-02-17 Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour lapreparation d'une composition pharmaceutique destinee a traiter la rosacee
PCT/FR2005/000367 WO2005089871A1 (fr) 2004-02-20 2005-02-17 Utilisation d’un compose antagoniste d’au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee
US10/590,077 US20070275978A1 (en) 2004-02-20 2005-02-17 Of at Use of an Antagonist Compound of at Least One Receptor Selected From a Group Comprising Beta-Adrenergic Receptors, A at1, 5-Ht5 and Galanin Receptor for Preparing a Pharmaceutical Composition for Treating Rosacea
EP05729329A EP1722855A1 (fr) 2004-02-20 2005-02-17 Utilisation d'un compose antagoniste d'au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d'une composition pharmaceutique destinee a traiter la rosacee

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0401715A FR2866567A1 (fr) 2004-02-20 2004-02-20 Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee

Publications (1)

Publication Number Publication Date
FR2866567A1 true FR2866567A1 (fr) 2005-08-26

Family

ID=34833940

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0401715A Pending FR2866567A1 (fr) 2004-02-20 2004-02-20 Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee

Country Status (5)

Country Link
US (1) US20070275978A1 (fr)
EP (1) EP1722855A1 (fr)
CA (1) CA2553208A1 (fr)
FR (1) FR2866567A1 (fr)
WO (1) WO2005089871A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216307A1 (fr) * 2016-06-16 2017-12-21 Almirall, S.A. Compositions comprenant du timolol et leur utilisation dans le traitement de la rosacée par administration topique
US20190231788A1 (en) * 2016-06-16 2019-08-01 Almirall, S.A. Compositions comprising timolol and an anti-inflammatory agent
WO2022007878A1 (fr) * 2020-07-10 2022-01-13 长庚医疗财团法人林口长庚纪念医院 UTILISATION D'UN ANTAGONISTE DE L'ADRÉNORÉCEPTEUR β-1 POUR LA PRÉPARATION D'UNE COMPOSITION DE RÉDUCTION DES LÉSIONS DES CELLULES ÉPITHÉLIALES INDUITES PAR L'INHIBITEUR DU RÉCEPTEUR DU FACTEUR DE CROISSANCE ÉPIDERMIQUE ET D'INHIBITION DES CELLULES CANCÉREUSES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002527A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine
WO2000029009A1 (fr) * 1998-11-18 2000-05-25 Coastside Bio Resources Peptides presentant une activite anticancereuse et anti-inflammatoire
WO2001035965A1 (fr) * 1999-11-18 2001-05-25 Bolla John D Traitement de l'acne rosacee

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758263B1 (fr) * 1997-01-16 1999-12-17 Oreal Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002527A1 (fr) * 1989-08-21 1991-03-07 Beth Israel Hospital Association Procede et composition de traitement d'hypersensibilite cutanee, oculaire et des muqueuses, d'etats inflammatoires et hyperproliferatifs en utilisant des preparations topiques d'antagonistes de serotonine
WO2000029009A1 (fr) * 1998-11-18 2000-05-25 Coastside Bio Resources Peptides presentant une activite anticancereuse et anti-inflammatoire
WO2001035965A1 (fr) * 1999-11-18 2001-05-25 Bolla John D Traitement de l'acne rosacee

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BERGSMA D J ET AL: "CLONING AND CHARACTERIZATION OF A HUMAN ANGIOTENSIN II TYPE 1 RECEPTOR", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 183, no. 3, 1992, pages 989 - 995, XP002145165, ISSN: 0006-291X *
ELLIS C N ET AL: "THE TREATMENT OF PERIORAL DERMATITIS, ACNE ROSACEA, AND SEBORRHEIC DERMATITIS", MEDICAL CLINICS OF NORTH AMERICA, W. B. SAUNDERS COMPANY, PHILADELPHIA, US, vol. 66, no. 4, July 1982 (1982-07-01), pages 819 - 830, XP008034382, ISSN: 0025-7125 *
JI R-R ET AL: "CENTRAL AND PERIPHERAL EXPRESSION OF GALANIN IN RESPONSE TO INFLAMMATION", NEUROSCIENCE, NEW YORK, NY, US, vol. 68, no. 2, September 1995 (1995-09-01), pages 563 - 576, XP001203559, ISSN: 0306-4522 *
REBORA A: "The red face: rosacea.", CLINICS IN DERMATOLOGY. 1993 APR-JUN, vol. 11, no. 2, April 1993 (1993-04-01), pages 225 - 234, XP009039132, ISSN: 0738-081X *
REES S ET AL: "CLONING AND CHARACTERISATION OF THE HUMAN 5-HT5A SEROTONIN RECEPTOR", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 355, 1994, pages 242 - 246, XP002919143, ISSN: 0014-5793 *
SULLIVAN K A ET AL: "PHARMACOLOGICAL CHARACTERIZATION AND TISSUE DISTRIBUTION OF THE HUMAN AND RAT GALR1 RECEPTORS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 233, 1997, pages 823 - 828, XP001184100, ISSN: 0006-291X *
WILKIN J K: "Recognizing and managing rosacea", DRUG THERAPY 1993 UNITED STATES, vol. 23, no. 6, 1993, pages 41 - 49, XP009039131, ISSN: 0001-7094 *

Also Published As

Publication number Publication date
WO2005089871A1 (fr) 2005-09-29
CA2553208A1 (fr) 2005-09-29
US20070275978A1 (en) 2007-11-29
EP1722855A1 (fr) 2006-11-22

Similar Documents

Publication Publication Date Title
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
MX2011012839A (es) Antagonistas policiclicos de receptores de acido lisofosfatidico.
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d'opioïdes
WO2010077883A3 (fr) Antagonistes des récepteurs d'acide lysophosphatidique
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
MX2009006304A (es) Nuevos compuestos de oxadiazol.
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
IL196409A (en) Annals of s-triazolyl-benzene sulfonamide and their pharmaceutical compositions
WO2007095161A3 (fr) Méthodes et compositions pour traiter des troubles associés à une augmentation du renouvellement osseux et une ostéopénie
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CL2007003817A1 (es) Agente terapeutico para la miopatia inflamatoria que comprende un antagonista de interleucina-6 (il-6).